Showing results (401-410 of 4,366) with videos related to

Sort By:
Pageof 437
Clinical Immunology (Orlando, Fla.)|May 13, 2004
Antigen-specific cytometry--new tools arrived!Andreas Thiel, Alexander Scheffold, Andreas Radbruch
Clinical Immunology (Orlando, Fla.)|May 13, 2004
Genomics in the immune systemTineke C M T van der Pouw Kraan, Pia V Kasperkovitz, Nicolette Verbeet, et al.
Clinical Immunology (Orlando, Fla.)|June 23, 2004
Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammationJohn L Prehn, Shahab Mehdizadeh, Carol J Landers, et al.
Clinical Immunology (Orlando, Fla.)|June 23, 2004
Modulation of tachykinin and cytokine release in patients with coronary disease undergoing percutaneous revascularizationMarino Paroli, Paola Mariani, Daniele Accapezzato, et al.
Clinical Immunology (Orlando, Fla.)|June 23, 2004
Hemagglutinating virus of Japan protein is efficient for induction of CD4+ T-cell response by a hepatitis B core particle-based HIV vaccineSatoshi Takeda, Kouichi Shiosaki, Yasufumi Kaneda, et al.
Clinical Immunology (Orlando, Fla.)|September 10, 2022
Bidirectional crosstalk between dysbiotic gut microbiota and systemic lupus erythematosus: What is new in therapeutic approaches?Hasnaa Yaigoub, Nada Fath, Hasna Tirichen, et al.
Clinical Immunology (Orlando, Fla.)|September 9, 2022
Liraglutide protects β-cells in novel human islet spheroid models of type 1 diabetesBurcak Yesildag, Joan Mir-Coll, Aparna Neelakandhan, et al.
Clinical Immunology (Orlando, Fla.)|February 27, 2021
Characterization of follicular T helper cells and donor-specific T helper cells in renal transplant patients with de novo donor-specific HLA-antibodiesJulien Subburayalu, Sebastian Dolff, Shilei Xu, et al.
Clinical Immunology (Orlando, Fla.)|March 1, 2019
Aberrant natural killer (NK) cell activation and dysfunction among ART-treated HIV-infected adults in an African cohortRose Nabatanzi, Lois Bayigga, Stephen Cose, et al.
Clinical Immunology (Orlando, Fla.)|March 1, 2019
Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumorsG Travis Clifton, Kaitlin M Peace, Jarrod P Holmes, et al.
Pageof 437